More than one in seven people in the US have chronic kidney disease (CKD), making it one of the top causes of death. Anaemia is a common, though under-treated complication.

Dr Robert Provenzano of Wayne State University and his team pooled together the results of three randomised clinical trials to investigate the efficacy and safety of of new treatment, Roxadustat, in managing the blood disease risks of CKD patients.

Read the original article: doi.org/10.2215/CJN.16191020

Read more in Research Features